Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and provided details for a conference call to discuss results, corporate highlights, and outlook. The press release was furnished as Exhibit 99.1 to this report. The information in this report, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act.
Senseonics Holdings (SENS) approved a 1-for-20 reverse stock split and reduced authorized common shares to 70,000,000. The action is set by a Certificate of Amendment and becomes effective at 4:05 p.m. Eastern Time on October 17, 2025. At the effective time, every twenty issued and outstanding common shares will be combined into one share, with no change to par value.
The split triggers proportional adjustments to outstanding stock options, restricted stock units, warrants, and the share reserves under equity plans. Fractional shares will not be issued; stockholders otherwise entitled to a fraction will receive a cash payment instead. The reverse split applies to all holders proportionately and does not change any holder’s ownership percentage, aside from effects related to fractional shares. The common stock is expected to begin trading on a split-adjusted basis on the NYSE American on October 20, 2025 under the symbol SENS.
Senseonics Holdings, Inc. reported preliminary, unaudited revenue of approximately $8.1 million for the third quarter of 2025. This represents a 91% increase compared to the third quarter of 2024, primarily driven by approximately 160% growth in new U.S. patients over the prior year period.
The company emphasized that these figures are preliminary estimates based on information currently available, have not been reviewed or audited by its independent registered public accounting firm, and may change when full third quarter 2025 financial statements are finalized and reviewed.
Senseonics Holdings, Inc. furnished an update on its business and finances by attaching a press release that includes preliminary, unaudited financial information for the quarter ended September 30, 2025. The company provided this update under the "Results of Operations and Financial Condition" section, indicating it covers recent operating performance and balance sheet trends. The press release, dated October 6, 2025, is included as Exhibit 99.1, while the cover page Inline XBRL data is included as Exhibit 104. The company emphasized that this information is being furnished rather than filed, which limits certain legal liabilities under the securities laws.
Senseonics Holdings director Douglas S. Prince received 19,673 shares of common stock on 10/01/2025 as payment under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. The shares were issued using the closing price of $0.413 on the NYSE American for that date, representing the reported cash-equivalent value of $8,124.95. After the issuance, the filing reports the reporting person beneficially owned 1,107,280 shares. The Form 4 was signed by an attorney-in-fact and filed on 10/03/2025.
Douglas A. Roeder, a director of Senseonics Holdings, Inc. (SENS), received 35,714 shares of common stock under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees. The shares were issued based on the NYSE American closing price of $0.413 per share on the transaction date, representing cash-equivalent compensation of $14,749.88. After this issuance, the reporting person beneficially owned 1,694,540 shares of the issuer’s common stock. The transaction is reported on a Form 4 and was filed by a single reporting person. The Form states the issuance was pursuant to the issuer’s director compensation policy and discloses the calculation used to determine the share amount.
Senseonics Holdings director Edward Fiorentino received 34,200 shares of common stock on 10/01/2025 under the company's non-employee director compensation policy. The shares were issued in lieu of a quarterly retainer; the filing states the number of shares equals $14,124.60 divided by the closing price of $0.413 per share on the NYSE American that day.
After the issuance, the reporting person beneficially owned 1,379,301 shares. The Form 4 was signed by attorney-in-fact Frederick T. Sullivan on 10/03/2025. The filing records this as a routine equity grant to a director under the disclosed compensation policy.
Senseonics Holdings, Inc. disclosed an insider transaction on a Form 4 showing a director received 31,174 shares of common stock on October 1, 2025. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, calculated as $12,874.86 divided by the $0.413 closing price on that date.
Following the transaction, the director beneficially owned 1,294,175 shares, held directly.
Senseonics Holdings, Inc. reported that its stockholders approved a proposal at a special meeting to allow the Board of Directors to implement a reverse stock split of the Company’s common stock. The approved amendments to the Amended and Restated Certificate of Incorporation permit a reverse split in a range from 1-for-10 to 1-for-20, with a proportionate reduction in the authorized number of shares of common stock, at any time prior to September 29, 2026, as determined by the Board in its sole discretion.
The proposal passed with 285,639,190 votes for, 178,232,358 votes against, and 5,014,498 abstentions, showing substantial but not unanimous support. This approval gives the Board flexibility to adjust the share count and share price structure in the future within the approved range.
Senseonics Holdings, Inc. (SENS) is asking shareholders to approve authority for its board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-20, at any time before September 29, 2026. The Special Meeting will be held virtually on September 29, 2025 and the record date is August 7, 2025 when 814,680,910 shares were outstanding. The board unanimously recommends a vote FOR the proposal to give management flexibility to raise the per-share trading price, address NYSE American minimum price criteria, potentially improve marketability and liquidity, and preserve flexibility for future corporate actions. No fractional shares will be issued; holders entitled to fractions will receive cash based on the five-day average closing price before the effective date. Approval requires a majority of votes properly cast.